Skip to main content
Top
Published in: Malaria Journal 1/2016

Open Access 01-12-2016 | Research

Feasibility and acceptability of injectable artesunate for the treatment of severe malaria in the Democratic Republic of Congo

Authors: Henry M. T. Ntuku, Gianfrancesco Ferrari, Christian Burri, Antoinette K. Tshefu, Didier M. Kalemwa, Christian Lengeler

Published in: Malaria Journal | Issue 1/2016

Login to get access

Abstract

Background

The Democratic Republic of the Congo (DRC) changed its national policy for the treatment of severe malaria in both children and adults in 2012 from intravenous quinine to injectable artesunate. The country is now planning to deploy nationwide injectable artesunate as the preferred treatment for the management of severe malaria. To support this process, the feasibility and acceptability of the use of injectable artesunate in the context of the DRC was assessed, from the perspective of both health care providers and patients/caretakers.

Methods

Questionnaires and observations were used to collect information from health care providers and patients/caretakers in eight health facilities in the Province of Kinshasa and in the Province of Bas-Congo.

Results

A total of 31 health care providers and 134 patients/care takers were interviewed. Seventy five percent (75 %) of health care providers found it less difficult to prepare injectable artesunate compared to quinine. None of them encountered problems during preparation and administration of injectable artesunate. The large majority of care providers (93 %) and patients/caretakers (93 %) answered that injectable artesunate took less time than quinine to cure the symptoms of the patients. 26 (84 %) health care providers reported that the personnel workload had diminished with the use of injectable artesunate. 7 (22.6 %) health workers reported adverse drug reactions, of which a decrease in the haemoglobin rate was the most common (71.4 %). All care providers and the vast majority of patients/caretakers (96 %, N = 128) were either satisfied or very satisfied with injectable artesunate.

Conclusions

These findings show that the use of injectable artesunate for the treatment of severe malaria is feasible and acceptable in the context of DRC, with appropriate training of care providers. Both care providers and patients/caretakers perceived injectable artesunate to be effective and safe, thus promoting acceptability.
Literature
1.
go back to reference PNLP. Plan Stratégique National de Lutte contre le Paludisme 2013–2015. Kinshasa: Ministère de la Santé; 2013. PNLP. Plan Stratégique National de Lutte contre le Paludisme 2013–2015. Kinshasa: Ministère de la Santé; 2013.
2.
go back to reference WHO. World malaria report. Geneva: World Health Organization; 2013. WHO. World malaria report. Geneva: World Health Organization; 2013.
3.
go back to reference PNLP. Rapport annuel d’activités 2012. Kinshasa: Ministère de la Santé; 2013. PNLP. Rapport annuel d’activités 2012. Kinshasa: Ministère de la Santé; 2013.
4.
go back to reference Likwela JL, Donnen P, Dramaix MW. Clinical aspects and outcome of suspected severe pediatric malaria. Méd Mal Infect. 2012;42:315–20.CrossRef Likwela JL, Donnen P, Dramaix MW. Clinical aspects and outcome of suspected severe pediatric malaria. Méd Mal Infect. 2012;42:315–20.CrossRef
5.
go back to reference Roll Back MalariaPartnership. Refined/Updated GMAP Objectives, Targets, Milestones and Priorities Beyond 2011. Geneva: Roll Back Malaria; 2011. Roll Back MalariaPartnership. Refined/Updated GMAP Objectives, Targets, Milestones and Priorities Beyond 2011. Geneva: Roll Back Malaria; 2011.
6.
go back to reference Sinclair D, Donegan S, Isba R, Lalloo D. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012;6:CD005967.PubMed Sinclair D, Donegan S, Isba R, Lalloo D. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012;6:CD005967.PubMed
7.
go back to reference Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717–25.PubMedCrossRef Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717–25.PubMedCrossRef
8.
go back to reference Dondorp AM, Fanello CI, Hendriksen ICE, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647–57.PubMedPubMedCentralCrossRef Dondorp AM, Fanello CI, Hendriksen ICE, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647–57.PubMedPubMedCentralCrossRef
9.
go back to reference WHO. Management of severe malaria. A practical handbook. Geneva: World Health Organization; 2013. WHO. Management of severe malaria. A practical handbook. Geneva: World Health Organization; 2013.
10.
go back to reference WHO. Guidelines for treatment of malaria. 2nd ed. Geneva: World Health Organization; 2011. WHO. Guidelines for treatment of malaria. 2nd ed. Geneva: World Health Organization; 2011.
12.
go back to reference PNLP. Directives nationales de traitement du paludisme en République Démocratique du Congo. Kinshasa: Ministère de la Santé; 2012. PNLP. Directives nationales de traitement du paludisme en République Démocratique du Congo. Kinshasa: Ministère de la Santé; 2012.
13.
go back to reference Burri C, Ferrari G, Ntuku HM, Tshefu AK, Duparc S, Hugo P, et al. Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: a manageable issue. Am J Trop Med Hyg. 2014;91:821–3.PubMedPubMedCentralCrossRef Burri C, Ferrari G, Ntuku HM, Tshefu AK, Duparc S, Hugo P, et al. Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: a manageable issue. Am J Trop Med Hyg. 2014;91:821–3.PubMedPubMedCentralCrossRef
14.
go back to reference Rolling T, Agbenyega T, Issifou S, Adegnika A, Sylverken J, Spahlinger D, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria—a double-center prospective study. J Infect Dis. 2014;209:1921–8.PubMedCrossRef Rolling T, Agbenyega T, Issifou S, Adegnika A, Sylverken J, Spahlinger D, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria—a double-center prospective study. J Infect Dis. 2014;209:1921–8.PubMedCrossRef
15.
go back to reference Rolling T, Wichmann D, Schmiedel S, Burchard GD, Kluge S, Cramer JP. Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis. Malar J. 2013;12:241.PubMedPubMedCentralCrossRef Rolling T, Wichmann D, Schmiedel S, Burchard GD, Kluge S, Cramer JP. Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis. Malar J. 2013;12:241.PubMedPubMedCentralCrossRef
16.
go back to reference Ferrari G, Ntuku HM, Burri C, Tshefu AK, Duparc S, Hugo P, et al. An operational comparative study between quinine and artesunate for the treatment of severe malaria in Hospitals and Health Centres of Kinshasa and Bas Congo in the Democratic Republic of Congo: the MATIAS study. Malar J. 2015;14:226.PubMedPubMedCentralCrossRef Ferrari G, Ntuku HM, Burri C, Tshefu AK, Duparc S, Hugo P, et al. An operational comparative study between quinine and artesunate for the treatment of severe malaria in Hospitals and Health Centres of Kinshasa and Bas Congo in the Democratic Republic of Congo: the MATIAS study. Malar J. 2015;14:226.PubMedPubMedCentralCrossRef
18.
go back to reference Taylor SM, Messina JP, Hand CC, Juliano J, Muwonga J, Tshefu AK, et al. Molecular malaria epidemiology: mapping and burden estimates for the Democratic Republic of the Congo, 2007. PLoS One. 2011;6:e16420.PubMedPubMedCentralCrossRef Taylor SM, Messina JP, Hand CC, Juliano J, Muwonga J, Tshefu AK, et al. Molecular malaria epidemiology: mapping and burden estimates for the Democratic Republic of the Congo, 2007. PLoS One. 2011;6:e16420.PubMedPubMedCentralCrossRef
21.
go back to reference Wolf LR, Otten EJ, Spadafora M. Cinchonism: two case reports and review of acute quinine toxicity and treatment. J Emerg Med. 1992;10:295–301.PubMedCrossRef Wolf LR, Otten EJ, Spadafora M. Cinchonism: two case reports and review of acute quinine toxicity and treatment. J Emerg Med. 1992;10:295–301.PubMedCrossRef
22.
go back to reference Sam-wobo SO, Agbeyangi OA, Ekpo UF, Akinloye OA, Mafiana CF, Adeleke MA. Rectal artesunates, their utilization, and parental perception in the management of malaria in children from Abeokuta, Southwestern Nigeria. Vector-Borne Zoonotic Dis. 2012;12:151–5.PubMedCrossRef Sam-wobo SO, Agbeyangi OA, Ekpo UF, Akinloye OA, Mafiana CF, Adeleke MA. Rectal artesunates, their utilization, and parental perception in the management of malaria in children from Abeokuta, Southwestern Nigeria. Vector-Borne Zoonotic Dis. 2012;12:151–5.PubMedCrossRef
Metadata
Title
Feasibility and acceptability of injectable artesunate for the treatment of severe malaria in the Democratic Republic of Congo
Authors
Henry M. T. Ntuku
Gianfrancesco Ferrari
Christian Burri
Antoinette K. Tshefu
Didier M. Kalemwa
Christian Lengeler
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2016
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-015-1072-x

Other articles of this Issue 1/2016

Malaria Journal 1/2016 Go to the issue